Unibest

Pharmaceutical intermediates

Sofosbuvir Intermediates

2 pharmaceutical intermediates for Sofosbuvir. Indication: Hepatitis C, Chronic; Hepatitis C.

提交项目All intermediates

About Sofosbuvir

Originator
Gilead Sciences Inc
Indication
Hepatitis C, Chronic; Hepatitis C
Approved Date
08/28/2019
DS/DP
03/21/2028

Available intermediates

2 intermediates currently listed for Sofosbuvir. Request specifications, documentation or a quotation for any item below.

Sofosbuvir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2'-Deoxy-2'-fluoro-2'- Methyl-N-(phenylcarbonyl) cytidine817204-32-3//
2'-deoxy-2'-fluoro-2'-C-methyluridine863329-66-2//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeladelparSeltorexantSemaglutideSitafloxacin hydrate

Building toward Sofosbuvir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →